Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

SZN-8141Positive

AI Analysis

Summary

Surrozen has submitted an IND application for SZN-8141, a candidate for treating diabetic macular edema. This represents an early-stage regulatory milestone enabling the company to initiate clinical trials.

Importance:5/10

Sentiment:

0.50

IND applicationdiabetic macular edemaophthalmologyregulatory milestone

Read the original article

Published by GlobeNewswire Clinical Studies on September 8, 2026 12:30 PM

Read Original